Abstract: Objective To investigate the secondary prevention medication and compliance of patients with coronary heart disease, and to provide a reference for controlling the condition of coronary heart disease. Methods From January 2021 to April 2022, patients diagnosed with coronary heart disease in the First Affiliated Hospital of Xinxiang Medical College were selected for investigation. The survey content included the basic information of patients, secondary prevention medication, and compliance. Descriptive analysis was used to analyze secondary prevention medication in patients with coronary heart disease, and univariate and multivariate analysis methods were used to analyze the influencing factors of compliance with secondary prevention medication. Results A total of 1 295 patients with coronary heart disease were included in this study for analysis. Of them, 964, 780, 679, and 482 patients were treated with aspirin/Clopidogrel sulfate, β-blockers, statins lipid‐lowering drugs, and angiotensin converting enzyme inhibitors （ACEI）/angiotensin receptor blocker （ARB）, accounting for 74.44%, 60.24%, 52.44%, and 37.22%, respectively. The compliance of 1 295 patients with coronary heart disease was 35.60% （461/1 295）. Multivariate Logistic regression analysis showed that gender （OR=2.331）, education level （OR=1.972）, living style （OR=3.009）, course of disease （OR=1.777）, other underlying diseases （OR=0.647）, daily times of medication （OR=0.583）, adverse drug reactions （OR=0.219） were the influencing factors for medication compliance in patients with coronary heart disease. Conclusions The status and compliance of secondary prevention medication in patients with coronary heart disease need to be improved. Gender, education level, living style, course of disease, other underlying diseases, daily times of medication, and adverse drug reactions can all affect the compliance of secondary prevention medication. It is recommended to focus on the above factors, strengthen the management of prevention medication, and promote the improvement of medication compliance, so as to control the development of disease.

Key words: Coronary heart disease, Secondary prevention, Compliance, Influencing factor